1. Patent reform in the US: what's at stake for pharmaceutical innovation?
- Author
-
Yancey A and Stewart CN Jr
- Subjects
- Biomedical Research economics, Drug Design, Drug Industry economics, Pharmaceutical Preparations economics, Time Factors, United States, Clinical Trials as Topic methods, Drug Industry legislation & jurisprudence, Patents as Topic legislation & jurisprudence
- Abstract
The current patent landscape in the US has not undergone major legislative reform since 1952. The US Senate version of the most recently proposed patent reform legislation puts forward a number of rule changes that could impact the pharmaceutical industry. Among the bill's major provisions are moving to a first-to-file system, changes to post-grant review and reexamination procedures, and damages reform. Various industries with a stake in patent reform have responded to the proposed changes. The need for balanced reform makes the stakes particularly high for the pharmaceutical industry which must invest a significant amount of time and money in the research and development process in exchange for already abbreviated patent lifetimes due to the lengthy clinical trial process.
- Published
- 2010
- Full Text
- View/download PDF